ClinicalTrials.gg
CompletedNCT01742676SINGLEUpdated Aug 5, 2014

A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients

A Phase 4 interventional study of ADVAGRAF and PROGRAF in Renal Transplantation, Kidney Transplantation and Stable Renal Recipients, sponsored by Astellas Pharma Korea, Inc.. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-08-05.

Sponsored by Astellas Pharma Korea, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate and compare the safety and efficacy of two drugs (ADVAGRAF® and PROGRAF® groups) in patients who received renal transplantation.

02

Conditions studied

  • Renal Transplantation
  • Kidney Transplantation
  • Stable Renal Recipients

Keywords

  • tacrolimus
  • kidney
03

In context

Lead sponsor

Astellas Pharma Korea, Inc. is the lead sponsor of 19 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Only patients who meet the following inclusion criteria should be enrolled.

  1. Patients who received a kidney at least within 12 months of their study enrollment (from a deceased or living donor)
  2. Patients whose tacrolimus dose have not been changed in at least 12 weeks from their study enrollment and whose minimum blood tacrolimus concentration mean value is within 3-10 ng/ml
  3. Female patients who showed a negative result in the serum pregnancy test and who agreed to use an effective method during the study period
  4. Patients who are clinically stable based on the judgment of the investigator
  5. Patients who were given enough information regarding the study, understood the objectives and risks of the study, and signed the form

Exclusion criteria

Exclusion Criteria:

Patients who fall under any of the following criteria should not be enrolled in this study.

  1. Patients who had received any other organ except a kidney
  2. Patients who showed an acute rejection reaction within 12 weeks of their enrollment or who showed an acute rejection reaction that required antilymphocyte antibody therapy within 24 weeks
  3. Patients who were diagnosed with a newly developed malignant tumor (Patients with successfully treated squamous cell/basal cell carcinoma can be enrolled, though.)
  4. Patients who have a known allergy to the drug (the test/control drug) or to tacrolimus
  5. Patients who have an unstable medical condition that may affect the evaluation of the study's objectives based on the investigator's judgment
  6. Patients who have any form of drug abuse or mental illness that might complicate communication with the investigators based on the investigator's judgment
  7. Patients who are currently participating in another clinical trial or who received the investigational drug in another trial within 28 days of their enrollment
  8. Patients who are receiving prohibited concomitant medications or who received those medications within 28 days of their enrollment
  9. Patients who are pregnant or breastfeeding
  10. Patients who had been -positive
  11. Patients who are considered non-compliant with the scheduled study visits in the protocol
  12. Patients who have abnormal kidney functions or a serum creatinine level higher than 1.6 mg/dL/ (MDRD) or less than 30 mL/min at the screening visit
  13. Patients who have "Creeping creatinine" (a 20% increase in their creatinine for six months before their enrollment)
  14. Patients who have abnormal liver functions: i.e., whose /ALT and/or SGOT/AST and/or is twice higher than the normal range in the center, and who have liver cirrhosis
  15. Patients who have an underlying disease such as focal segmental glomerulosclerosis (FSGS) or type II membranoproliferative glomerulonephritis (Type II MPGN)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    ADVAGRAF group

    Drug: ADVAGRAF

  • Active comparator
    PROGRAF group

    Drug: PROGRAF

Interventions

  • oral

    Also known as: modified release tacrolimus

  • oral

    Also known as: twice-daily tacrolimus

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Time frame: at 24 weeks

Secondary outcomes

  1. Glomerular Filtration Rate (GFR)

    Calculated by Modification of Diet in Renal Disease equation

    Time frame: at 24 weeks

  2. Incidence of rejection reactions

    Time frame: at 24 weeks

  3. Blood pressure

    Time frame: at 24 weeks

  4. Survival rate of the grafts

    Time frame: at 24 weeks

  5. Subject's physical condition (SF-35)

    Evaluation of subject's physical condition

    Time frame: at 24 weeks

07

Study locations

1 site
  • Seoul, Korea, Republic of
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2012
First posted
Dec 5, 2012
Start
Apr 2011
Primary completionActual
Apr 2013
CompletionActual
Apr 2013
Last update
Aug 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01742676
Responsible party
Sponsor
First posted
Dec 5, 2012
Start date
Apr 2011
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Aug 5, 2014

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion